https://scholars.lib.ntu.edu.tw/handle/123456789/638444
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Simonelli, M | en_US |
dc.contributor.author | Garralda, E | en_US |
dc.contributor.author | Eskens, F | en_US |
dc.contributor.author | Gil-Martin, M | en_US |
dc.contributor.author | Yen, C-J | en_US |
dc.contributor.author | Obermannova, R | en_US |
dc.contributor.author | Chao, Y | en_US |
dc.contributor.author | Lonardi, S | en_US |
dc.contributor.author | Melichar, B | en_US |
dc.contributor.author | Moreno, V | en_US |
dc.contributor.author | Yu, M-L | en_US |
dc.contributor.author | Bongiovanni, A | en_US |
dc.contributor.author | Calvo, E | en_US |
dc.contributor.author | Rottey, S | en_US |
dc.contributor.author | Machiels, J-P | en_US |
dc.contributor.author | Gonzalez-Martin, A | en_US |
dc.contributor.author | Paz-Ares, L | en_US |
dc.contributor.author | Chang, C-L | en_US |
dc.contributor.author | Mason, W | en_US |
dc.contributor.author | CHIA-CHI LIN | en_US |
dc.contributor.author | Reardon, D A | en_US |
dc.contributor.author | Vieito, M | en_US |
dc.contributor.author | Santoro, A | en_US |
dc.contributor.author | Meng, R | en_US |
dc.contributor.author | Abbadessa, G | en_US |
dc.contributor.author | Menas, F | en_US |
dc.contributor.author | Lee, H | en_US |
dc.contributor.author | Liu, Q | en_US |
dc.contributor.author | Combeau, C | en_US |
dc.contributor.author | Ternes, N | en_US |
dc.contributor.author | Ziti-Ljajic, S | en_US |
dc.contributor.author | Massard, C | en_US |
dc.date.accessioned | 2024-01-12T07:58:33Z | - |
dc.date.available | 2024-01-12T07:58:33Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 20597029 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/638444 | - |
dc.description.abstract | The anti-CD38 antibody isatuximab is approved for the treatment of relapsed/refractory multiple myeloma, but there are no data on its efficacy in solid tumors. This phase I/II study (NCT03637764) assessed the safety and activity of isatuximab plus atezolizumab (Isa + Atezo), an anti-programmed death-ligand 1 (PD-L1) antibody, in patients with immunotherapy-naive solid tumors: epithelial ovarian cancer (EOC), glioblastoma (GBM), hepatocellular carcinoma (HCC), and squamous cell carcinoma of the head and neck (SCCHN). | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | ESMO open | en_US |
dc.subject | anti-CD38; anti-PD-L1; atezolizumab; isatuximab; solid tumors | en_US |
dc.title | Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1016/j.esmoop.2022.100562 | - |
dc.identifier.pmid | 35987165 | - |
dc.identifier.scopus | 2-s2.0-85136683326 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85136683326 | - |
dc.relation.journalvolume | 7 | en_US |
dc.relation.journalissue | 5 | en_US |
item.openairetype | journal article | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.fulltext | no fulltext | - |
item.languageiso639-1 | en | - |
item.grantfulltext | none | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。